Screener
Bicara Therapeutics BCAX Interest Income
Interest Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Bicara Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:InvestmentIncomeInterest.
The source filing: Bicara Therapeutics’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:03 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-033429
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Total operating expenses | 60,242 | 41,788 |
| Loss from operations | (60,242) | (41,788) |
| Other income | ||
| Interest income | 4,083 | 5,014 |
| Total other income | 4,083 | 5,014 |
| Net loss before income taxes | (56,159) | (36,774) |
| Income tax expense | (52) | (72) |
| Net loss | $(56,211) | $(36,846) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Bicara Therapeutics's interest income?
- Bicara Therapeutics (BCAX) reported interest income of $4.08M in Q1 2026.
- How has Bicara Therapeutics's interest income changed year-over-year?
- Bicara Therapeutics's interest income decreased by 18.6% year-over-year, from $5.01M to $4.08M.
- What does interest income mean?
- Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.
Ask your AI about Bicara Therapeutics's interest income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude